←Crohn Disease
Study register · detail Narrative Review · Crohn Disease · 2018

The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report

Abrams et al. ·European Journal of Internal Medicine Impact 3.3
Mixed 294 citations
SampleNarrative Review
EndpointTherapeutic efficacy
Blindingunklar
DesignNarrative Review
Key finding

Strong evidence for pain, nausea and MS spasticity, weak to absent evidence for most other therapeutic indications.

Summary

Update of the National Academies of Sciences report on therapeutic effects of cannabis (Abrams 2018); consolidates evidence for chronic pain, MS spasticity, chemotherapy-induced nausea; for Crohn's disease, limited evidence for symptomatic relief in the absence of an anti-inflammatory effect is summarized.

P
PopulationAdults with various conditions (pain, nausea, spasticity, sleep disorders, among others) — approx. 10.000 abstracts screened
I
InterventionCannabis and cannabinoids (various forms of administration and indications)
O
OutcomeConclusive/substantial evidence for pain, chemotherapy-induced nausea/vomiting and MS spasticity; moderate evidence for sleep disorders; limited/insufficient evidence for appetite, Tourette, anxiety, PTSD, cancer, irritable bowel syndrome, epilepsy and neurodegenerative diseases
Quality profile
Sample size —
Blinding —
Effect size Mixed
Citations / year ★★★★★
Authors
Abrams D I
DOI 10.1016/j.ejim.2018.01.003↗
Design: Narrative Review
Share
Indication
Further studies on Crohn Disease
All studies →
S Mack et al. · 2019 · Gastroenterology
73 citations
Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.
Unclear Systematic Review

Canadian Association of Gastroenterology Clinical Practice Guideline für pädiatrischen Morbus Crohn; 25 Statements nach GRADE-Methodik. Empfiehlt gegen Cannabis in jeder Rolle bei pädiatrischem Morbus Crohn. Systematische Evidenzbewertung durch iterativen Konsensusprozess.

10.1053/j.gastro.2019.03.022 View study →
A Naftali et al. · 2021 · Journal of Crohn's and Colitis
77 citations
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial
Mixed RCT (double-blind, placebo-controlled)

Naftali et al. 2021 — doppelblinde RCT, n=56 Morbus-Crohn-Patienten (30 Cannabis, 26 Placebo); CBD-reiches Cannabisöl (160/40 mg/ml CBD/THC) vs. Placebo über 8 Wochen. CDAI-Reduktion signifikant in Cannabis-Gruppe (Median 282→166) vs. Placebo (264→237), p<0.05. Quality-of-Life-Score verbessert (74→91 Cannabis vs. 74→75 Placebo, p=0.004). KEINE signifikante Änderung bei endoskopischem Score (SES-CD) oder Entzündungsmarkern (CRP, Calprotectin, p=0.75). Klinische Remission ohne endoskopische oder inflammatorische Verbesserung; gut verträglich.

10.1093/ecco-jcc/jjab069 View study →
A Langhorst et al. · 2015 · Journal of Crohn's and Colitis
198 citations
Systematic Review of Complementary and Alternative Medicine Treatments in Inflammatory Bowel Diseases
Mixed Systematic Review

Systematische Review zu Komplementär- und Alternativmedizin bei IBD (Morbus Crohn und Colitis ulcerosa); k=39 Studien (26 RCTs + 3 CTs zu Phytotherapeutika, 7 RCTs zu Mind/Body-Interventionen, 2 RCTs zu Akupunktur, 1 RCT zu Trichuris suis). Evaluierte u.a. Cannabis als Phytotherapeutikum. Beste Evidenz für Plantago ovata und Curcumin bei UC-Erhaltungstherapie, Wermut bei CD, Mind/Body-Therapie bei UC, Akupunktur bei UC und CD. Heterogene methodische Qualität (Cochrane Risk of Bias).

10.1093/ecco-jcc/jju007 View study →

The impediment to action advances action. — Marcus Aurelius